alexa The Economic Impact of Pharmacotherapeutic Follow-Up in
ISSN: 2376-0419

Journal of Pharmaceutical Care & Health Systems
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

The Economic Impact of Pharmacotherapeutic Follow-Up in Copd Patients at a Health Care Institution in Medellin-Colombia

Jorge I Estrada*, Ana M Restrepo, Robinson Herrera, Juan Arrieta, Juan A Serna and Angela M Segura
Help Pharma, Street number 34, 43A-155, Office 249, Mall Almacentro, Colombia
Corresponding Author : Estrada JI
National Research Coordinator, Help Pharma, Street number 34
43A-155, Office 249, Mall Almacentro (Medellin-Antioquia)
Tel: +574-4037-510
E-mail: [email protected]
Received May 07, 2015; Accepted May 12, 2015; Published May 15, 2015
Citation: Estrada JI, Restrepo AM, Herrera R, Arrieta J, Serna JA, et al. (2015) The Economic Impact of Pharmacotherapeutic Follow-Up in Copd Patients at a Health Care Institution in Medellin-Colombia. J Pharma Care Health Sys 2:137. doi:10.4172/2376-0419.1000137
Copyright: © 2015 Estrada JI, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Context: several studies show that missing doses and an incorrect inhalation technique, are the most common pharmacological risks in patients with Chronic Obstructive Pulmonary Disease diagnosis. These are associated with an increase in Health-related costs, mainly due to an increase in the number of emergency visits, hospitalizations and switches of medication as a consequence of therapeutic failures. Objective: to determinate the median cost per month of each patient stratified by type of pharmacological risks, after pharmacotherapeutic follow-up assessment. Method: Follow-up cohort, in Chronic Obstructive Pulmonary Disease patients. The observation period was from January 2012 to June 2014 [n:108]. The pharmacological risks assessed were incorrect inhalation technique and missing doses. The main outcome was the median cost per month in each patient before and after having received Health-related education by a Pharmacist, stratified by having or not pharmacological risks [1 USD=1.906,9COP information to august 2014]. Wilcoxon test for paired sample and U de Mann-Whitney test for independent sample were used for this purpose. Results: The median cost per month was 165, 3[104,0-277,8], a patient without pharmacological risks was 119,2 [88,9-201,4] USD and a patient with pharmacological risks was 186,7 [123,7-307,9] [p= 0,033]. On the other hand, a patient with missing doses was 195,1 [131,6-297,6], in comparison with a patient with incorrect inhalation technique, that was 143,0 [96,3-169,0]. The cost before the Pharmacotherapeutic Follow-up implementation was 169,8 [110,8-253,8] and after that it was 150,7 [106,7-278,1], with an important decrease of 11,25% [p= 0,517]. Conclusion: Having pharmacological risks was related with a higher median cost per patient. The median cost per patient was lower after giving Health-related education to patients by Pharmacotherapeutic Follow-up.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version